Back
There are some reports indicated that rates of AKI were negligible among COVID-19 patients. Nevertheless, there is a growing evidence that demonstrated that AKI is in fact prevalent among patients diagnosed with COVID-19 particularly among in-patients. Given the vulnerability of people who develop AKI from COVID-19 infection, the immediate call for vaccination to everyone became the primary importance. Whether COVID-19 vaccines confer the same level of protection and adverse effects to the general population is not yet known. The rapid and mass vaccination to COVID-19 has been one of the key strategies to control and fight the pandemic. Despite the recognition of AKI as a frequent complication of COVID-19, there is lack of local consensus data regarding its incidence and outcomes. Here we attempted to bridge this knowledge gap and helped establish a steady baseline data. Also, we explored AKI after COVID-19 vaccine administration in association to incidence, prevalence and the different risk factors that could intervene to improve prognosis.
A retrospective observational cohort study of critically ill adult patients with COVID-19 in tertiary hospital in Pasig, Philippines. Baseline characteristics, COVID-19 treatments, AKI incidence, risk factors and outcomes for 306 patients diagnosed with COVID-19 who were hospitalized from January 2021 to February 2022.
There was insufficient evidence to determine association of COVID-19 vaccine in general with incidence of AKI, while the severity and poor outcomes were higher in the unvaccinated cohort.Causality needs further identification. with incidence of AKI, while the severity and poor outcomes were higher in the unvaccinated cohort. Causality needs further identification.